Ezra's Notes Checked November 16, 2026
Investor Holdings

By @ezracrangle

← All managers

Kahn Brothers Group

Kahn Brothers Group

How they invest Deep value · Obscure and out of favor · Long holding periods

Why I follow Kahn

Irving Kahn was Ben Graham's teaching assistant at Columbia and started the firm with his sons in 1978; he died in 2015, at 109. The firm still looks for the obscure and the out of favor, and Citigroup, Merck, Pfizer, BP and Exxon Mobil are in every 13F since 2013.

Portfolio at the end of Q3 2026

From the 13F filed November 16, 2026. See the filing on EDGAR ↗

CompanyWeightValueSharesPriceHeld sinceChange
Citigroup C · history 17.8% $107.4M 829,645 $129.48 Q2 2013 or earlier Reduce 1%
Bayer BAYRY · history 14.4% $86.7M 6,423,358 $13.50 Q4 2023 Reduce 1%
Flagstar Financial FLG · history 7.9% $47.3M 4,051,827 $11.67 Q2 2013 or earlier Reduce 1%
Alphabet GOOG · history 6.7% $40.2M 118,113 $340.74 Q2 2025 Reduce 2%
Disney DIS · history 6.2% $37.1M 353,847 $104.90 Q1 2024 Reduce 1%
Zillow Z · history 6.0% $36.2M 1,334,321 $27.13 Q1 2026 Add 13%
Merck MRK · history 4.9% $29.7M 204,238 $145.31 Q2 2013 or earlier Reduce 6%
BP BP · history 4.5% $27.3M 621,049 $43.99 Q2 2013 or earlier Reduce 1%
IDT IDT · history 4.2% $25.3M 316,325 $79.97 Q2 2013 or earlier Reduce 10%
Seaport Entertainment SEG · history 3.6% $21.4M 934,535 $22.89 Q3 2025 Add 2%
Shake Shack SHAK · history 3.5% $21.3M 362,315 $58.68 Q3 2026 Buy
Seaboard SEB · history 3.3% $19.6M 4,959 $3,948.00 Q2 2013 or earlier Reduce 8%
Organon OGN · history 3.2% $19.3M 1,408,069 $13.70 Q2 2021 Reduce 47%
Patterson-UTI Energy PTEN · history 3.0% $18.1M 1,655,592 $10.92 Q2 2013 or earlier No change
MBIA MBI · history 3.0% $17.9M 4,204,370 $4.26 Q3 2025 No change
Pfizer PFE · history 1.9% $11.5M 403,301 $28.52 Q2 2013 or earlier Reduce 13%
Bristol-Myers Squibb BMY · history 1.6% $9.7M 155,297 $62.40 Q2 2013 or earlier Reduce 11%
GSK GSK · history 0.9% $5.5M 113,552 $48.17 Q3 2014 Reduce 28%
Exxon Mobil XOM · history 0.4% $2.6M 16,105 $162.75 Q2 2013 or earlier Reduce 9%
First National Bank Alaska FBAK · history 0.3% $1.6M 4,920 $328.50 Q2 2019 No change
Genie Energy GNE · history 0.3% $1.6M 101,113 $15.98 Q2 2013 or earlier Reduce 33%
Novartis NVS · history 0.3% $1.6M 11,286 $142.57 Q2 2013 or earlier Reduce 14%
CSX CSX · history 0.3% $1.6M 34,231 $46.51 Q3 2023 Reduce 2%
Tourmaline Oil TOU · history 0.2% $1.2M 26,959 $42.90 Q4 2024 No change
Fairfax Financial FRFHF · history 0.2% $1.2M 738 $1,563.16 Q1 2024 Reduce 28%
Microsoft MSFT · history 0.2% $1.1M 2,168 $512.90 Q1 2024 No change
Apple AAPL · history 0.2% $1.0M 3,092 $333.02 Q1 2024 No change
JPMorgan Chase JPM · history 0.2% $949K 2,868 $330.83 Q1 2020 No change
SEI Investments SEIC · history 0.1% $677K 6,596 $102.66 Q3 2024 No change
Peyto Exploration & Development PEYUF · history 0.1% $480K 29,807 $16.10 Q3 2019 Reduce 5%
Windrock Land Company 97349V107 · history 0.1% $436K 792 $551.00 Q1 2025 Reduce 2%
Haleon HLN · history 0.1% $412K 45,789 $9.00 Q3 2022 Reduce 22%
Chevron CVX · history 0.1% $399K 1,953 $204.21 Q1 2025 No change
Bank of America BAC · history 0.1% $395K 7,259 $54.43 Q2 2013 or earlier Reduce 23%
Deutsche Bank DB · history 0.1% $359K 10,000 $35.89 Q3 2024 No change
Orange County Bancorp OBT · history 0.0% $296K 8,000 $36.95 Q2 2025 No change
Garrett Motion GTX · history 0.0% $284K 10,918 $26.03 Q3 2026 Buy
Verizon VZ · history 0.0% $261K 5,682 $45.87 Q2 2019 No change
Blackstone BX · history 0.0% $258K 2,300 $112.09 Q1 2025 No change
PNC PNC · history 0.0% $251K 1,130 $222.26 Q1 2024 Reduce 16%
Procter & Gamble PG · history 0.0% $249K 1,712 $145.28 Q1 2022 Reduce 2%
Antero Midstream AM · history 0.0% $238K 11,806 $20.16 Q1 2024 No change
PSEG PEG · history 0.0% $237K 3,524 $67.34 Q1 2024 No change
PepsiCo PEP · history 0.0% $228K 1,800 $126.72 Q3 2019 No change
IBM IBM · history 0.0% $226K 1,028 $219.93 Q3 2024 Reduce 16%
Pine Cliff Energy PIFYF · history 0.0% $189K 526,000 $0.36 Q2 2025 Add 1%
Rafael RFL · history 0.0% $62K 46,746 $1.32 Q1 2018 Reduce 69%
TPHGreenwich Trust 008997017 · history 0.0% $0 166,999 Q4 2025 No change
48 positions100.0%$601.8M

Weight is the position's share of the total value in this 13F, not of the whole fund. Price is the value divided by the number of shares, so it's the price at the end of the quarter, as the firm reported it. Change compares share counts with Q2 2026, adjusted for stock splits.

Sector weighting

Sector weights in this 13F
Financials & real estate35.8%
Health care27.3%
Media & telecom14.0%
Energy8.4%
Technology7.1%
Consumer discretionary3.6%
Consumer staples3.4%
Utilities0.3%
Industrials0.3%

By quarter

Sectors come from each company's industry code at the SEC (SIC), grouped broadly. The codes are old and coarse: Amazon counts as retail, Alphabet as software. How sectors work.

Every position, quarter by quarter

Each row is a company in today's 50 biggest positions (two share classes of one company share a row), each square a quarter. The darker the square, the bigger the position's weight in that 13F. Hover or tap a square for the number.

What changed from Q2 2026

Every quarter on file

QuarterTop holdingsPositionsValue
Q3 2026filed Nov 16, 2026 Citigroup 17.8% · Bayer 14.4% · Flagstar Financial 7.9% 48 $601.8M
Q2 2026filed Aug 17, 2026 Citigroup 18.5% · Bayer 14.1% · Flagstar Financial 9.6% 48 $632.7M
Q1 2026filed May 8, 2026 Citigroup 16.9% · Bayer 13.3% · Flagstar Financial 9.5% 48 $564.1M
Q4 2025filed Feb 12, 2026 Citigroup 18.1% · Bayer 12.9% · Flagstar Financial 9.3% 54 $564.7M
Q3 2025filed Nov 12, 2025 Citigroup 16.7% · Bayer 10.6% · Flagstar Financial 9.3% 53 $531.8M
Q2 2025filed Aug 14, 2025 Citigroup 15.2% · Bayer 10.2% · Disney 9.8% 50 $497.9M
Q1 2025filed May 15, 2025 Citigroup 12.6% · Flagstar Financial 9.9% · Merck 8.9% 55 $494.5M
Q4 2024filed Feb 14, 2025 Citigroup 13.9% · Merck 11.0% · Disney 8.5% 52 $460.4M
Q3 2024filed Nov 13, 2024 Citigroup 12.8% · Merck 11.4% · BP 8.6% 53 $580.6M
Q2 2024filed Aug 14, 2024 Citigroup 12.7% · Merck 12.3% · BP 10.0% 52 $595.0M
Q1 2024filed May 15, 2024 Assured Guaranty 12.6% · Merck 12.0% · Citigroup 11.2% 53 $674.4M
Q4 2023filed Feb 13, 2024 Assured Guaranty 11.6% · Merck 10.7% · Flagstar Financial 9.9% 43 $634.8M
Q3 2023filed Nov 13, 2023 Flagstar Financial 11.1% · BP 10.7% · Merck 10.3% 43 $640.9M
Q2 2023filed Aug 9, 2023 Merck 11.0% · Flagstar Financial 10.5% · BP 9.5% 43 $682.1M
Q1 2023filed May 12, 2023 BP 10.7% · Merck 10.3% · Bristol-Myers Squibb 9.0% 45 $694.7M
Q4 2022filed Feb 15, 2023 Assured Guaranty 10.1% · Merck 10.0% · BP 10.0% 45 $759.6M
Q3 2022filed Nov 15, 2022 Bristol-Myers Squibb 10.2% · BP 9.7% · Assured Guaranty 9.4% 45 $641.74B
Q2 2022filed Aug 10, 2022 Patterson-UTI Energy 10.2% · Assured Guaranty 9.8% · Bristol-Myers Squibb 9.6% 45 $742.71B
Q1 2022filed May 2, 2022 Patterson-UTI Energy 11.4% · Assured Guaranty 10.7% · MBIA 9.4% 46 $787.55B
Q4 2021filed Jan 25, 2022 MBIA 10.8% · Assured Guaranty 9.9% · GSK 8.7% 43 $728.03B
Q3 2021filed Nov 1, 2021 Assured Guaranty 9.4% · MBIA 9.0% · BP 8.8% 43 $710.35B
Q2 2021filed Aug 4, 2021 Assured Guaranty 9.9% · Citigroup 8.5% · Bristol-Myers Squibb 8.4% 43 $698.34B
Q1 2021filed May 7, 2021 Assured Guaranty 9.6% · Citigroup 9.4% · Flagstar Financial 8.8% 42 $646.07B
Q4 2020filed Feb 11, 2021 Merck 10.4% · Bristol-Myers Squibb 9.4% · Citigroup 8.8% 42 $573.28B
Q3 2020filed Nov 6, 2020 Merck 12.6% · Bristol-Myers Squibb 10.7% · GSK 10.0% 42 $527.50B
Q2 2020filed Aug 3, 2020 Merck 12.1% · GSK 10.5% · Bristol-Myers Squibb 10.1% 47 $591.79B
Q1 2020filed May 11, 2020 Merck 14.1% · GSK 10.7% · Bristol-Myers Squibb 10.5% 48 $546.73B
Q4 2019filed Jan 27, 2020 Merck 11.4% · Citigroup 9.8% · Assured Guaranty 9.1% 47 $824.73B
Q3 2019filed Nov 5, 2019 Merck 11.3% · Citigroup 9.2% · Assured Guaranty 8.8% 48 $797.58B
Q2 2019filed Aug 5, 2019 Merck 11.2% · Citigroup 9.7% · BP 8.7% 44 $799.87B
Q1 2019filed May 6, 2019 Merck 10.8% · BP 9.4% · Citigroup 8.9% 32 $640.04B
Q4 2018filed Jan 29, 2019 Merck 11.0% · BP 9.6% · Citigroup 8.9% 31 $554.66B
Q3 2018filed Oct 30, 2018 Citigroup 10.2% · BP 9.9% · Merck 9.7% 31 $651.15B
Q2 2018filed Aug 6, 2018 BP 10.1% · Citigroup 10.0% · Merck 8.7% 31 $628.43B
Q1 2018filed May 1, 2018 Citigroup 10.2% · BP 9.1% · New York Times 8.7% 31 $627.75B
Q4 2017filed Jan 25, 2018 Citigroup 11.5% · BP 9.3% · New York Times 8.4% 31 $636.58B
Q3 2017filed Nov 7, 2017 Citigroup 11.2% · New York Times 9.3% · Merck 9.0% 34 $654.54B
Q2 2017filed Aug 8, 2017 Citigroup 10.5% · New York Times 9.3% · Merck 9.1% 34 $655.75B
Q1 2017filed May 8, 2017 Citigroup 11.1% · Merck 10.3% · New York Times 9.2% 35 $581.40B
Q4 2016filed Jan 31, 2017 Citigroup 10.9% · Merck 9.5% · New York Times 8.4% 35 $592.10B
Q3 2016filed Nov 1, 2016 Merck 10.8% · Citigroup 9.4% · Hologic 8.7% 35 $552.09B
Q2 2016filed Aug 9, 2016 Merck 10.8% · Citigroup 9.0% · New York Times 8.8% 37 $516.56B
Q1 2016filed May 9, 2016 Merck 9.8% · New York Times 9.1% · Citigroup 8.9% 37 $533.88B
Q4 2015filed Feb 8, 2016 Citigroup 10.4% · Merck 9.5% · New York Times 9.4% 38 $559.66B
Q3 2015filed Nov 9, 2015 Citigroup 10.3% · Hologic 9.7% · Pfizer 9.7% 38 $540.19B
Q2 2015filed Jul 28, 2015 Citigroup 10.5% · Pfizer 10.0% · Merck 9.8% 40 $593.05B
Q1 2015filed May 6, 2015 Pfizer 10.6% · Merck 10.0% · Citigroup 9.8% 42 $592.07B
Q4 2014filed Feb 3, 2015 Citigroup 11.1% · Merck 10.3% · Pfizer 10.1% 44 $580.19B
Q3 2014filed Nov 6, 2014 Merck 10.7% · Citigroup 10.4% · Pfizer 9.5% 44 $614.81B
Q2 2014filed Aug 6, 2014 New York Times 10.0% · Citigroup 9.5% · Merck 9.4% 43 $687.33B
Q1 2014filed May 7, 2014 New York Times 11.7% · Pfizer 9.7% · Merck 9.1% 42 $700.51B
Q4 2013filed Feb 4, 2014 New York Times 11.6% · Pfizer 10.0% · Citigroup 9.6% 42 $581.04B
Q3 2013filed Nov 6, 2013 Pfizer 10.5% · New York Times 9.9% · Citigroup 9.7% 43 $687.29B
Q2 2013filed Aug 9, 2013 Pfizer 11.0% · Citigroup 10.1% · New York Times 9.2% 46 $648.04B